These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22112972)

  • 21. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.
    Salm F; Cwiek P; Ghosal A; Lucia Buccarello A; Largey F; Wotzkow C; Höland K; Styp-Rekowska B; Djonov V; Zlobec I; Bodmer N; Gross N; Westermann F; Schäfer SC; Arcaro A
    Oncogene; 2013 Aug; 32(34):3944-53. PubMed ID: 23027129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
    Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype.
    Lopes EC; Garcia M; Benavides F; Shen J; Conti CJ; Alvarez E; Hajos SE
    Leuk Res; 2003 May; 27(5):413-23. PubMed ID: 12620293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
    Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
    Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.
    Ugarenko M; Nudelman A; Rephaeli A; Kimura K; Phillips DR; Cutts SM
    Biochem Pharmacol; 2010 Feb; 79(3):339-49. PubMed ID: 19737541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.
    Doi K; Li R; Sung SS; Wu H; Liu Y; Manieri W; Krishnegowda G; Awwad A; Dewey A; Liu X; Amin S; Cheng C; Qin Y; Schonbrunn E; Daughdrill G; Loughran TP; Sebti S; Wang HG
    J Biol Chem; 2012 Mar; 287(13):10224-10235. PubMed ID: 22311987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
    Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Qiu HB; Zhang LY
    Ai Zheng; 2009 Sep; 28(9):932-8. PubMed ID: 19728910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BH3 mimetics to improve cancer therapy; mechanisms and examples.
    Zhang L; Ming L; Yu J
    Drug Resist Updat; 2007 Dec; 10(6):207-17. PubMed ID: 17921043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
    BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells.
    Huang Y; Ibrado AM; Reed JC; Bullock G; Ray S; Tang C; Bhalla K
    Leukemia; 1997 Feb; 11(2):253-7. PubMed ID: 9009089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.
    Jayanthan A; Howard SC; Trippett T; Horton T; Whitlock JA; Daisley L; Lewis V; Narendran A
    Leuk Lymphoma; 2009 Jul; 50(7):1174-82. PubMed ID: 19557638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
    van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
    Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
    Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
    Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens.
    Anvekar RA; Asciolla JJ; Lopez-Rivera E; Floros KV; Izadmehr S; Elkholi R; Belbin G; Sikora AG; Chipuk JE
    Cell Death Dis; 2012 Nov; 3(11):e420. PubMed ID: 23152056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins).
    Notarbartolo M; Cervello M; Dusonchet L; Cusimano A; D'Alessandro N
    Cancer Lett; 2002 Jun; 180(1):91-101. PubMed ID: 11911975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
    Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.
    Kohl TM; Hellinger C; Ahmed F; Buske C; Hiddemann W; Bohlander SK; Spiekermann K
    Leukemia; 2007 Aug; 21(8):1763-72. PubMed ID: 17554384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.